Bristol-Myers Squibb Company Ce
Bristol-Myers Squibb Company Ce Fundamental Analysis
Bristol-Myers Squibb Company Ce (CELG-RI) shows strong financial fundamentals with a PE ratio of 0.03, profit margin of 14.64%, and ROE of 39.27%. The company generates $48.2B in annual revenue with moderate year-over-year growth of 7.32%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -17.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CELG-RI's fundamental strength across five key dimensions:
Efficiency Score
WeakCELG-RI struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCELG-RI trades at attractive valuation levels.
Growth Score
ModerateCELG-RI shows steady but slowing expansion.
Financial Health Score
WeakCELG-RI carries high financial risk with limited liquidity.
Profitability Score
ModerateCELG-RI maintains healthy but balanced margins.
Key Financial Metrics
Is CELG-RI Expensive or Cheap?
P/E Ratio
CELG-RI trades at 0.03 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CELG-RI's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Bristol-Myers Squibb Company Ce at 0.01 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -2.26 times EBITDA. This is generally considered low.
How Well Does CELG-RI Make Money?
Net Profit Margin
For every $100 in sales, Bristol-Myers Squibb Company Ce keeps $14.64 as profit after all expenses.
Operating Margin
Core operations generate 31.36 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $39.27 in profit for every $100 of shareholder equity.
ROA
Bristol-Myers Squibb Company Ce generates $7.83 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bristol-Myers Squibb Company Ce generates strong operating cash flow of $14.16B, reflecting robust business health.
Free Cash Flow
Bristol-Myers Squibb Company Ce generates strong free cash flow of $12.85B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $6.31 in free cash annually.
FCF Yield
CELG-RI converts 75.81% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.03
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.002
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.01
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.004
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.65
vs 25 benchmark
Current Ratio
Current assets to current liabilities
-13.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.39
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.16
vs 25 benchmark
How CELG-RI Stacks Against Its Sector Peers
| Metric | CELG-RI Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.03 | 29.43 | Better (Cheaper) |
| ROE | 39.27% | 800.00% | Weak |
| Net Margin | 14.64% | -20145.00% (disorted) | Strong |
| Debt/Equity | 2.65 | 0.30 | Weak (High Leverage) |
| Current Ratio | -13.00 | 4.64 | Weak Liquidity |
| ROA | 7.83% | -17936.00% (disorted) | Weak |
CELG-RI outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bristol-Myers Squibb Company Ce's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
55.39%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-318.86%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
58.39%
Industry Style: Defensive, Growth, Innovation
High Growth